Table 1

Schedule of assessments

Randomisation andbaseline4weeks*±1week
FU visit		6 months±2 months FU visit12 months±2 months FU visit
Confirm eligibility✓
Seek informed consent✓
Randomisation✓
Medical history†✓
Medication review✓✓✓✓
Physical examination✓‡§ ✓‡§ ✓‡§
Office blood pressure✓✓✓✓
Pulse✓✓✓✓
Standard care blood tests✓‡ ✓‡ ✓‡
Height✓‡
Weight✓‡ ✓‡ ✓‡ ✓‡
Administer EQ 5D-5L✓✓✓
Resource use (Follow-Up CRFs)✓✓
Dispense trial medication*✓
Adverse event review and evaluation✓✓✓
Adherence✓✓
Qualitative interviews**✓††✓

  • *Carvedilol arm only.

  • †Including aetiology of liver disease and past medical history (diabetes, ischaemic heart disease, pulmonary disease). AUDIC-C score will also be calculated where appropriate.

  • ‡Taken from clinical records.

  • §Liver stiffness measurement using Fibroscan where available and appropriate.

  • ¶Medication may initially be dispensed by site but can subsequently be dispensed by the participant’s community pharmacy.

  • **Pilot phase only.

  • ††Follow-up qualitative interviews will be between 6 and 12 months.

  • CRF, Case Report Form.